Hyperpolarized Pyruvate Imaging for Brain Tumors
Trial Summary
What is the purpose of this trial?
Upwards of 40% of cancer patients will develop brain metastases during their illness, most of which become symptomatic. The burden of brain metastases impacts the quality and length of survival. Thus the management of brain metastases is a significant health care problem. Standard treatment options include stereotactic radiosurgery and/or whole brain radiation. There is a great interest in studying the association between the functional characteristics of tumors - such as tumour hypoxia and lactate accumulation - and clinical outcomes in order to guide management. These characteristics may predict future tumor behavior and stratify risk of therapy failure. Hyperpolarized 13C MR imaging is a novel functional imaging technique that uses 13C-labeled molecules, such as pyruvate, and MRS to image in vivo tissue metabolism. There is significant clinical heterogeneity in patients with brain metastasis due to differences in underlying tumour biology. Biochemical differences in tumour metabolism have been shown to correlate with response to therapy. While the significance of tissue hypoxia for radiosensitivity has been established for years, the impact of lactate accumulation on radiosensitivity has only recently been recognized. Studies have shown that tissue lactate levels correlate with radioresistance in several human tumours. Hyperpolarized 13C pyruvate MRS has been shown in numerous pre-clinical studies and a recent clinical study to have great potential as a metabolic imaging tool. Our study seeks to establish the role of hyperpolarized 13C MRS in characterizing the metabolic features of intracranial metastasis. The results of this study will provide insight into intracranial metastatic disease signatures with MR spectroscopy and determine if there is added benefit for incorporation of this new technique into future clinical MRI protocols. If the technique can accurately differentiate between aggressive and indolent tumours based on MR spectroscopic patterns, hyperpolarized 13C MRS may have wide-ranging utility in the future. In the era of personalized medicine, the ability of imaging tests to predict response to therapy would open the door for individualized treatment options specific to each patient's disease biology.
Research Team
Charles Cunningham, PhD
Principal Investigator
Sunnybrook Research Institute
Eligibility Criteria
Adults of any ethnicity with brain metastases from solid cancers, at least one tumor over 1 cm suitable for radiosurgery or radiotherapy, on a stable steroid dose, expected to live more than 6 months. Excludes those with prior brain radiotherapy for the lesion in question, certain cognitive impairments, MRI contraindications like pacemakers or severe claustrophobia, known reactions to contrast agents used in MRIs, and inability to lie still.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
MRI and Hyperpolarized 13C Pyruvate Injection
Participants undergo MRI sequences with hyperpolarized 13C pyruvate injection to assess metabolic features of intracranial metastasis
Radiation Treatment Planning
Participants undergo routine radiation planning scan with additional MRI sequences
Post-Radiation MRI
Participants undergo a non-routine MRI scan 1-5 days following radiation treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Hyperpolarized 13C-Pyruvate
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sunnybrook Health Sciences Centre
Lead Sponsor